NON SMALL CELL LUNG CANCER METASTATIC
Clinical trials for NON SMALL CELL LUNG CANCER METASTATIC explained in plain language.
Never miss a new study
Get alerted when new NON SMALL CELL LUNG CANCER METASTATIC trials appear
Sign up with your email to follow new studies for NON SMALL CELL LUNG CANCER METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for Tough-to-Treat lung cancer
Disease control OngoingThis study tests an experimental drug called patritumab deruxtecan in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to other treatments. About 277 participants will receive the drug to see if it shrinks tumors. The go…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New staggered drug combo aims to outsmart lung cancer
Disease control OngoingThis phase II study tests two staggered schedules of the immunotherapy drug durvalumab combined with standard chemotherapy (pemetrexed and carboplatin) in 43 adults with advanced non-squamous non-small cell lung cancer. The goal is to see if changing the timing of the drugs impro…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Old drugs, new hope? ceritinib and docetaxel team up against tough lung cancer
Disease control OngoingThis early-phase study tests whether combining two cancer drugs—ceritinib and docetaxel—can safely help people with advanced non-small cell lung cancer that has not responded to other treatments. About 21 adults with stage IIIB or IV disease will receive the drugs to find the bes…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for tough lung cancers: drug combo trial launches
Disease control OngoingThis trial tests a new drug called acasunlimab, either alone or combined with the cancer drug pembrolizumab, in people with advanced non-small cell lung cancer that has come back or stopped responding to standard treatments. About 125 adults will receive the drugs intravenously e…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo tackles lung cancer after immunotherapy fails
Disease control OngoingThis study tests a combination of three drugs—bevacizumab, nab-paclitaxel, and a platinum drug—as a second-line treatment for people with advanced non-squamous non-small cell lung cancer that does not have certain genetic mutations. The cancer must have worsened after first-line …
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: NA • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Triple drug cocktail shows promise against tough lung cancer
Disease control OngoingThis study is testing whether a combination of three drugs—nivolumab, ipilimumab, and nintedanib—can safely shrink tumors in people with advanced non-small cell lung cancer that has no curative options. The trial involves 66 participants and is split into two phases: the first fi…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for Hard-to-Treat lung cancer: which combo works best?
Disease control OngoingThis study tests two different chemotherapy plus immunotherapy combinations in people with advanced lung cancer that has a specific marker (TTF-1 negative). About 136 participants will be randomly assigned to one of two treatment groups. The goal is to see which combination helps…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE4 • Sponsor: Nikolaj Frost MD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy aims to slow liver and lung cancers
Disease control OngoingThis phase 2 trial is testing the drugs atezolizumab and bevacizumab in 36 people with inoperable liver cancer or non-small cell lung cancer that has spread to the liver. The goal is to see how long the cancer stays under control and to study changes in tumors and blood before an…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo attack on lung cancer: adding radiation to immunotherapy and chemo
Disease control OngoingThis Phase 3 trial tests whether adding radiation to the standard combination of pembrolizumab (an immunotherapy) and chemotherapy can improve survival in people with advanced non-small cell lung cancer. About 327 participants with stage IIIB/IV disease will receive either the tr…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New dual-action antibody enters early trials for tough-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a precise radiation burst stall Cancer's spread?
Disease control OngoingThis study tests whether giving stereotactic body radiotherapy (SBRT) to growing metastatic tumors can delay overall cancer progression. About 107 adults with triple-negative breast cancer or non-small cell lung cancer that has started to grow in a few spots will receive SBRT or …
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Hope for elderly lung cancer patients: immunotherapy combo under study
Disease control OngoingThis study looks at whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps elderly patients (70+) with advanced non-small cell lung cancer live longer. About 510 participants will receive either chemotherapy alone or chemotherapy plus atezolizumab. The …
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for rare lung cancer: lorlatinib targets resistant tumors
Disease control OngoingThis phase 2 trial tests the drug lorlatinib in 54 people with advanced ROS1-positive non-small cell lung cancer whose cancer has stopped responding to initial targeted therapy. Lorlatinib is designed to overcome resistance and reach the brain. Researchers will measure how many p…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for rare lung cancer mutations? dacomitinib under study
Disease control OngoingThis phase 2 trial is testing the targeted drug dacomitinib in 30 people with advanced non-small cell lung cancer that has uncommon EGFR mutations. Participants take a daily pill until their cancer worsens or side effects become too severe. The study aims to see how well the drug…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:07 UTC
-
Digital nudge aims to speed up genetic testing for lung cancer
Knowledge-focused OngoingThis study tests whether an electronic health record reminder (a 'nudge') can prompt doctors to order genetic tests for patients newly diagnosed with advanced non-small cell lung cancer. The goal is to have test results available before starting treatment, so doctors can choose t…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: NA • Sponsor: Charu Aggarwal • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC